Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Langerhans cell sarcoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Langerhans cell sarcoma. Displaying page 1 of 1.
    EudraCT Number: 2020-005051-20 Sponsor Protocol Number: HISTIOGEN Start Date*: Information not available in EudraCT
    Sponsor Name:Institute of Mother and Child
    Full Title: Determination Of Molecular Status And Benefit Of Use Fludeoxyglucose (18F-FDG) In PET/CT imagining In Juvenile Patients With Histiocytosis
    Medical condition: histiocytic cell proliferation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078782 Langerhans cell sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060801 Erdheim-Chester disease PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063397 Rosai-Dorfman syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005052-37 Sponsor Protocol Number: BRAVO Start Date*: 2021-04-01
    Sponsor Name:Institute of Mother and Child
    Full Title: Optymalizacja czasu leczenia i dawkowania wemurafenibu u małoletnich pacjentów z opornymi na konwencjonalną terapię rozrostami z komórek histiocytarnych z obecnością mutacji w genie BRAF.
    Medical condition: histiocytic cell proliferation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078782 Langerhans cell sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060801 Erdheim-Chester disease PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063397 Rosai-Dorfman syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005053-25 Sponsor Protocol Number: TRAM Start Date*: Information not available in EudraCT
    Sponsor Name:Institute of Mother and Child
    Full Title: Optimalization Of The Time And Dosage Of Trametinib In BRAF Negative Juvenile Patients With Refractory Histiocytosis Or After Failure Of Vemurafenib Treatment.
    Medical condition: histiocytic cell proliferation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078782 Langerhans cell sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060801 Erdheim-Chester disease PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063397 Rosai-Dorfman syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000425-45 Sponsor Protocol Number: Start Date*: 2012-07-03
    Sponsor Name:
    Full Title: Effects of morning vs evening dosing on the pharmacokinetics and pharmacodynamics of sunitinib.
    Medical condition: Renal Cell Cancer, GIST, pancreatic neuroendocrine tumor
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055008 Gastric sarcoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000461-23 Sponsor Protocol Number: CA209-627 Start Date*: 2017-03-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies
    Medical condition: Advanced/Metastatic malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 01:47:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA